Vaxcyte, Inc. (NASDAQ:PCVX) is Driehaus Capital Management LLC’s 10th Largest Position

Driehaus Capital Management LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 3.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,934,747 shares of the company’s stock after purchasing an additional 66,940 shares during the quarter. Vaxcyte accounts for approximately 1.4% of Driehaus Capital Management LLC’s holdings, making the stock its 10th biggest position. Driehaus Capital Management LLC’s holdings in Vaxcyte were worth $146,093,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PCVX. The Manufacturers Life Insurance Company lifted its stake in shares of Vaxcyte by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,749 shares of the company’s stock worth $9,948,000 after acquiring an additional 12,667 shares during the period. Maverick Capital Ltd. lifted its position in Vaxcyte by 93.7% in the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after purchasing an additional 332,777 shares during the period. AQR Capital Management LLC lifted its position in Vaxcyte by 3.1% in the second quarter. AQR Capital Management LLC now owns 10,860 shares of the company’s stock valued at $820,000 after purchasing an additional 328 shares during the period. Squarepoint Ops LLC acquired a new position in Vaxcyte during the 2nd quarter worth approximately $1,764,000. Finally, First Light Asset Management LLC increased its position in Vaxcyte by 131.8% during the 2nd quarter. First Light Asset Management LLC now owns 139,729 shares of the company’s stock worth $10,551,000 after purchasing an additional 79,445 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC upped their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Trading Up 1.5 %

Shares of PCVX opened at $113.14 on Friday. The company has a 50-day moving average of $92.24 and a two-hundred day moving average of $77.80. The stock has a market cap of $12.31 billion, a P/E ratio of -26.43 and a beta of 0.97. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same period last year, the company earned ($0.70) EPS. As a group, analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,479,005.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $40,351,102.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The disclosure for this sale can be found here. Insiders sold a total of 78,283 shares of company stock valued at $7,064,138 over the last three months. 3.10% of the stock is currently owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.